Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 62%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is experiencing a positive outlook due to promising developments in its targeted therapeutics, particularly with darovasertib, which has shown significant anti-tumor efficacy and improved visual acuity in patients with metastatic uveal melanoma. The company is advancing towards potential registration pathways with two Phase 3 trials currently underway, suggesting strong chances for successful outcomes and a substantial revenue upside, estimated to exceed $3.2 billion. Furthermore, the integration of darovasertib with crizotinib demonstrates enhanced efficacy and safety, bolstering investor confidence in the company's growth and market potential in precision oncology.

Bears say

The financial outlook for IDEAYA Biosciences Inc. is characterized by significant uncertainty stemming from the unpredictability of future revenues and expenses, compounded by its current non-revenue-generating status. Risk factors such as potential negative trial outcomes, regulatory hurdles, and challenges related to intellectual property could materially impede the commercialization of its therapeutic candidates, including darovasertib and IDE397. Additionally, the reliance on a limited pipeline and the potential for disappointing data in ongoing studies may undermine investor confidence and contribute to stock price volatility, suggesting substantial risk for the company’s financial performance.

IDYA has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 62% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 13 analysts, IDYA has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.